FDA “Follow-On” Biologics Framework Development Will Become More Public

FDA's development of a framework for "follow-on" biologics will become a more public process after the agency resolves internal questions about scientific issues, Office of New Drugs Deputy Director Sandra Kweder, MD, said April 16